Cartalax

Cartalax is a synthetic tripeptide bioregulator (Ala-Glu-Asp, also known as AED or T-31) developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. This short peptide has gained attention for its potential to support cartilage health, connective tissue integrity, and cellular anti-aging processes. Cartalax is particularly popular among individuals seeking joint support, those experiencing age-related cartilage degradation, and biohackers interested in geroprotective compounds. Typical dosages range from 2,000–5,000 mcg daily via subcutaneous injection, with protocols generally spanning 8–12 weeks.

What Is Cartalax?

Cartalax belongs to a class of compounds known as Khavinson peptides or bioregulatory peptides—ultrashort peptides consisting of 2–4 amino acid residues that are believed to interact with DNA and regulate gene expression at the cellular level. The peptide sequence (Ala-Glu-Asp) corresponds to a motif found in the alpha-1 chain of type XI collagen, a structural protein critical for cartilage integrity and connective tissue function.

What makes Cartalax unique among peptides is its tissue-specific targeting. Unlike broader-acting compounds, Cartalax appears to have particular affinity for cartilage and connective tissue cells, making it a specialized option for those focused on joint health and musculoskeletal support.

The primary human-use benefits attributed to Cartalax include:

 
• Supporting cartilage resilience and joint health
 
• Promoting fibroblast proliferation and function
 
• Modulating cellular senescence markers
 
• Supporting extracellular matrix homeostasis
 
• Potential anti-inflammatory properties at the cellular level

How It Works

Gene Expression Regulation

Cartalax operates through a mechanism distinct from most peptides. Research from Khavinson's laboratory demonstrates that short peptides like Cartalax can penetrate cell nuclei and interact directly with DNA, influencing gene expression and protein synthesis. The peptide has been shown to regulate genes involved in cell differentiation, functional activity, and aging processes.

Specifically, Cartalax (AED) has been documented to regulate the expression of genes associated with neuronal cell differentiation, cartilage function, and skin fibroblast activity. This epigenetic mechanism allows the peptide to influence cellular behavior at a fundamental level.

Chondrocyte and Fibroblast Modulation

In preclinical studies, Cartalax has demonstrated the ability to stimulate chondrocyte activity—the cells responsible for cartilage maintenance and regeneration. By upregulating Ki-67 (a proliferation marker) and increasing SIRT-1/SIRT-6 expression, the peptide may support cellular vitality in aging tissues.

The peptide also appears to reduce pro-apoptotic signaling by decreasing p53 and caspase-3 activity, potentially protecting cells from premature death and supporting tissue longevity.

Extracellular Matrix Support

Cartalax has been reported to inhibit MMP-9 synthesis—an enzyme linked to extracellular matrix degradation. This action may help preserve the structural integrity of cartilage and connective tissues, which naturally deteriorate with age.

Dosage Protocols

Based on available preclinical data and observational protocols, the following dosage framework is commonly referenced:

Standard Gradual Approach:

• Weeks 1–2: 2,000 mcg (2.0 mg) daily
• Weeks 3–4: 3,000 mcg (3.0 mg) daily
• Weeks 5–8: 4,000 mcg (4.0 mg) daily
• Weeks 9–12: 5,000 mcg (5.0 mg) daily

Cycle Length: 8–12 weeks is standard, with optional extension to 16 weeks.

Oral/Sublingual Form: Russian manufacturers also produce sublingual versions with a standard dosage of 10 drops (0.5 mL) under the tongue twice daily.

How to Use / Administration

Subcutaneous Injection:

1. Reconstitute the lyophilized powder with 3.0 mL bacteriostatic water (yields approximately 6.67 mg/mL concentration for a 20 mg vial)
2. Draw the appropriate dose using a U-100 insulin syringe
3. Clean the injection site with an alcohol swab
4. Pinch a skinfold and insert the needle at a 45–90° angle into subcutaneous tissue
5. Inject slowly and steadily
6. Rotate injection sites (abdomen, thighs, upper arms) to prevent local irritation

Timing: Administer at any consistent time daily. Some users prefer morning administration.

Results Timelines

Given the mechanism of action through gene expression modulation, Cartalax is not expected to produce immediate effects. Based on the nature of bioregulatory peptides and user reports:

• Weeks 1–4: Minimal noticeable changes; cellular-level processes initiating
• Weeks 4–8: Some users report subtle improvements in joint comfort and mobility
• Weeks 8–12: More pronounced effects on joint function and tissue resilience may become apparent
• Post-cycle: Benefits may persist for several weeks to months after discontinuation due to the epigenetic nature of the peptide's action

It is important to note that individual responses vary significantly, and the subtle nature of bioregulatory peptides means effects may be more preventive than immediately therapeutic.

Research Evidence

The scientific foundation for Cartalax comes primarily from Russian research institutions, particularly the Saint Petersburg Institute of Bioregulation and Gerontology. Key findings include:

A systematic review published in Molecules (2021) documented that the AED peptide (Cartalax) regulates cartilage and skin fibroblast functions, neuronal cell differentiation, and demonstrates DNA-binding capabilities.

Research published in the Bulletin of Experimental Biology and Medicine (2016) demonstrated that Cartalax affects Ki-67, CD98hc, caspase-3, and MMP-9 expression in skin fibroblast cultures during aging.

A 2014 study showed that Cartalax regulates the expression of signaling molecules (p53, p16, SIRT-6) in kidney cell cultures during in vitro aging.

Limitations: Most published data derives from in vitro or rodent models. Large-scale human randomized controlled trials are lacking, and much of the clinical experience comes from observational use in Russia.

Stacking

Cartalax can be combined with other peptides for synergistic effects on joint and tissue health:

With BPC-157 and TB-500: This combination targets multiple aspects of tissue repair. While BPC-157 and TB-500 are broadly used for tendon, ligament, and muscle injuries, Cartalax adds specific cartilage and connective tissue support.

With GHK-Cu: Both peptides support collagen synthesis and extracellular matrix health, potentially enhancing overall connective tissue benefits.

With other Khavinson peptides: Cartalax may be combined with Vesugen (cardiovascular support) or Pinealon (neuroprotection) for comprehensive anti-aging protocols.

When stacking, maintain separate injection sites and consider staggering administration times.

Reconstitution, Storage & Prep

Reconstitution:

1. Allow the vial to reach room temperature before opening
2. Draw 3.0 mL bacteriostatic water with a sterile syringe
3. Insert the needle through the stopper and let diluent run slowly down the vial wall
4. Gently swirl or roll until fully dissolved—do not shake
5. Label with date and concentration

Storage:

• Lyophilized (powder): Store at 2–8°C (35.6–46.4°F) or freeze at −20°C (−4°F) for long-term storage
• Reconstituted: Refrigerate at 2–8°C (35.6–46.4°F); use within 4–6 weeks
• Protect from light and moisture
• Avoid freeze-thaw cycles

Side Effects

Cartalax is generally reported as well-tolerated based on observational data from Russian clinical use and preclinical studies:

Commonly reported:

• Mild injection-site reactions (redness, itching, minor swelling)
• Occasional mild gastrointestinal upset
• Transient fatigue in some users

Important considerations:

• No serious adverse events have been documented in available literature
• Long-term safety data from controlled human trials is limited
• As with any injectable, proper sterile technique is essential to prevent infection

Legal Status / FDA

Cartalax is not approved by the FDA as a drug or dietary supplement. In the United States, it is sold strictly for research purposes only and is not intended for human consumption under federal regulations.

In Russia, Khavinson peptides including Cartalax have been used clinically and are available as registered products. The regulatory status varies significantly by country, and users should verify local laws before obtaining or using this peptide.

Sports / WADA

While Cartalax is not specifically named on the World Anti-Doping Agency (WADA) Prohibited List, athletes should exercise caution. WADA prohibits certain categories of peptides, particularly peptide hormones and growth factors.

Collagen-derived peptides are generally not prohibited, as WADA has clarified that "collagen peptides" are distinct from "peptide hormones." However, the regulatory landscape for novel peptides remains complex, and competitive athletes should consult with their sport's anti-doping authority before use.

WADA has developed detection methods capable of identifying peptides under 2 kDa, which would include Cartalax (molecular weight 333.29).

Conclusion

Cartalax represents an intriguing entry in the bioregulatory peptide category, offering a targeted approach to cartilage and connective tissue support through gene expression modulation. Its mechanism of action—interacting directly with DNA to influence cellular behavior—distinguishes it from more conventional peptides. While the preclinical evidence is promising, particularly regarding fibroblast function and cellular senescence markers, the lack of large-scale human clinical trials means users should approach with appropriate expectations. For those seeking joint support and interested in the emerging field of peptide bioregulation, Cartalax offers a research-backed option with a favorable safety profile based on available data.

FAQ

What is Cartalax made of?
Cartalax is a synthetic tripeptide consisting of three amino acids: alanine, glutamic acid, and aspartic acid (Ala-Glu-Asp or AED). Its sequence corresponds to a motif found in type XI collagen.

How long does it take for Cartalax to work?
Due to its mechanism of action through gene expression modulation, noticeable effects typically require 4–8 weeks of consistent use. Some users report subtle improvements in joint comfort within the first month, with more pronounced benefits appearing after 8–12 weeks.

Can Cartalax be taken orally?
Yes, sublingual formulations are available, particularly from Russian manufacturers. The standard oral dosage is 10 drops (0.5 mL) under the tongue twice daily. However, subcutaneous injection is considered more bioavailable.

Is Cartalax the same as collagen supplements?
No. While Cartalax's sequence is derived from type XI collagen, it functions as a bioregulatory peptide that influences gene expression rather than providing structural collagen building blocks like traditional collagen supplements.

Can Cartalax be stacked with BPC-157?
Yes, many users combine Cartalax with BPC-157 and/or TB-500 for comprehensive tissue repair support. Cartalax targets cartilage specifically, while BPC-157 and TB-500 offer broader soft tissue healing benefits.

Who developed Cartalax?
Cartalax was developed by Professor Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, as part of extensive research into bioregulatory peptides spanning several decades.

Is Cartalax safe for long-term use?
Based on available observational data, Khavinson peptides including Cartalax have been described as well-tolerated. However, long-term safety data from controlled human trials is limited. Cycling protocols (8–12 weeks on, followed by a break) are commonly recommended.

Does Cartalax require a prescription?
In the United States, Cartalax is not FDA-approved and is sold for research purposes only. Regulatory status varies by country. In Russia, it is available as a registered product.